Biodesix announces abstracts presented during the iaslc 2021 world conference on lung cancer

Boulder, colo.--(business wire)---- $bdsx #patientsfirst--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that two abstracts highlighting proteomic and genomic data based on their diagnostic tests were presented at the international association for the study of lung cancer (iaslc) world conference on lung cancer (wclc). the role of serum proteomic signature in predicting survival by pd-l1 status in patients with non-small cell lung cancer r
BDSX Ratings Summary
BDSX Quant Ranking